Inhibition of skin 11β-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids

Jon Hennebold, Raymond A. Daynes

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Synthetic forms of glucocorticoids (GCs) with high potency are widely used to treat a number of dermatological conditions having an inflammatory or autoimmune etiology. While GCs are generally effective in their ability to suppress inflammatory processes, their chronic use can lead to detrimental systemic side effects. In this report, we describe a method by which the localized antiinflammatory potential of the natural GC cortisol can be significantly augmented without increasing the risk of negative systemic effects. 11β-Hydroxysteroid dehydrogenase (11β-HSD) is a naturally occurring enzyme in the skin, 11β-HSD functionally converts biologically active 11-hydroxy GCs to their biologically inactive 11-keto metabolites, thereby limiting the ability of GCs to mediate antiinflammatory activities. By topically applying specific inhibitors of 11β-HSD in conjunction with low doses of GCs, the antiinflammatory properties of cortisol can be significantly potentiated. It was observed that the generation of the effector phase of contact hypersensitivity (CH) responses could be suppressed by this combined treatment under conditions where the 11β-HSD inhibitor alone, or cortisol alone were only minimally effective. Only the combined treatment was effective at inhibiting the progression of an ongoing CH response.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalArchives of Dermatological Research
Volume290
Issue number8
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Glucocorticoids
Anti-Inflammatory Agents
Skin
Hydrocortisone
Contact Dermatitis
Enzymes

Keywords

  • 11 α-hydroxyprogesterone
  • 11β-hydroxysteroid dehydrogenase
  • Contact hypersensitivity
  • Glucocorticoids
  • Glycyrrhetinic acid

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{f0017ab4b13046879e71e485db88cca7,
title = "Inhibition of skin 11β-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids",
abstract = "Synthetic forms of glucocorticoids (GCs) with high potency are widely used to treat a number of dermatological conditions having an inflammatory or autoimmune etiology. While GCs are generally effective in their ability to suppress inflammatory processes, their chronic use can lead to detrimental systemic side effects. In this report, we describe a method by which the localized antiinflammatory potential of the natural GC cortisol can be significantly augmented without increasing the risk of negative systemic effects. 11β-Hydroxysteroid dehydrogenase (11β-HSD) is a naturally occurring enzyme in the skin, 11β-HSD functionally converts biologically active 11-hydroxy GCs to their biologically inactive 11-keto metabolites, thereby limiting the ability of GCs to mediate antiinflammatory activities. By topically applying specific inhibitors of 11β-HSD in conjunction with low doses of GCs, the antiinflammatory properties of cortisol can be significantly potentiated. It was observed that the generation of the effector phase of contact hypersensitivity (CH) responses could be suppressed by this combined treatment under conditions where the 11β-HSD inhibitor alone, or cortisol alone were only minimally effective. Only the combined treatment was effective at inhibiting the progression of an ongoing CH response.",
keywords = "11 α-hydroxyprogesterone, 11β-hydroxysteroid dehydrogenase, Contact hypersensitivity, Glucocorticoids, Glycyrrhetinic acid",
author = "Jon Hennebold and Daynes, {Raymond A.}",
year = "1998",
doi = "10.1007/s004030050328",
language = "English (US)",
volume = "290",
pages = "413--419",
journal = "Archives of Dermatological Research",
issn = "0340-3696",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Inhibition of skin 11β-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids

AU - Hennebold, Jon

AU - Daynes, Raymond A.

PY - 1998

Y1 - 1998

N2 - Synthetic forms of glucocorticoids (GCs) with high potency are widely used to treat a number of dermatological conditions having an inflammatory or autoimmune etiology. While GCs are generally effective in their ability to suppress inflammatory processes, their chronic use can lead to detrimental systemic side effects. In this report, we describe a method by which the localized antiinflammatory potential of the natural GC cortisol can be significantly augmented without increasing the risk of negative systemic effects. 11β-Hydroxysteroid dehydrogenase (11β-HSD) is a naturally occurring enzyme in the skin, 11β-HSD functionally converts biologically active 11-hydroxy GCs to their biologically inactive 11-keto metabolites, thereby limiting the ability of GCs to mediate antiinflammatory activities. By topically applying specific inhibitors of 11β-HSD in conjunction with low doses of GCs, the antiinflammatory properties of cortisol can be significantly potentiated. It was observed that the generation of the effector phase of contact hypersensitivity (CH) responses could be suppressed by this combined treatment under conditions where the 11β-HSD inhibitor alone, or cortisol alone were only minimally effective. Only the combined treatment was effective at inhibiting the progression of an ongoing CH response.

AB - Synthetic forms of glucocorticoids (GCs) with high potency are widely used to treat a number of dermatological conditions having an inflammatory or autoimmune etiology. While GCs are generally effective in their ability to suppress inflammatory processes, their chronic use can lead to detrimental systemic side effects. In this report, we describe a method by which the localized antiinflammatory potential of the natural GC cortisol can be significantly augmented without increasing the risk of negative systemic effects. 11β-Hydroxysteroid dehydrogenase (11β-HSD) is a naturally occurring enzyme in the skin, 11β-HSD functionally converts biologically active 11-hydroxy GCs to their biologically inactive 11-keto metabolites, thereby limiting the ability of GCs to mediate antiinflammatory activities. By topically applying specific inhibitors of 11β-HSD in conjunction with low doses of GCs, the antiinflammatory properties of cortisol can be significantly potentiated. It was observed that the generation of the effector phase of contact hypersensitivity (CH) responses could be suppressed by this combined treatment under conditions where the 11β-HSD inhibitor alone, or cortisol alone were only minimally effective. Only the combined treatment was effective at inhibiting the progression of an ongoing CH response.

KW - 11 α-hydroxyprogesterone

KW - 11β-hydroxysteroid dehydrogenase

KW - Contact hypersensitivity

KW - Glucocorticoids

KW - Glycyrrhetinic acid

UR - http://www.scopus.com/inward/record.url?scp=0031595816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031595816&partnerID=8YFLogxK

U2 - 10.1007/s004030050328

DO - 10.1007/s004030050328

M3 - Article

C2 - 9763302

AN - SCOPUS:0031595816

VL - 290

SP - 413

EP - 419

JO - Archives of Dermatological Research

JF - Archives of Dermatological Research

SN - 0340-3696

IS - 8

ER -